How GLP-1 Receptor Agonists Transformed the Treatment of Obesity and Diabetes

Keywords: Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA), Incretin, Obesity, Type 2 Diabetes, Cardiovascular Outcomes, Tirzepatide, Semaglutide, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Dual Agonist, Triple Agonist

Introduction

The global burden of metabolic disease has reached epidemic proportions. As of 2024, more than 1.9 billion adults worldwide are classified as overweight or obese, and over 800 million individuals live with type 2 diabetes mellitus. These conditions are not merely quantitative, they represent the leading upstream drivers of cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnoea, polycystic ovary syndrome (PCOS), and multiple cancers. Despite decades of effort, pharmacological obesity management remained largely ineffective until the emergence of potent, receptor-targeted peptide therapeutics [1,2].

GLP-1 receptor agonists, synthetic analogs of the endogenous incretin hormone glucagon-like peptide-1 have transformed this landscape with a speed and scope unprecedented in the history of metabolic pharmacotherapy. The approval of semaglutide 2.4 mg (Wegovy) for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023, represented a step-change: for the first time, pharmacological agents delivered weight reductions approaching surgical outcomes in pivotal randomized trials [3-6].

This category review examines the pharmacology, clinical evidence, comparative efficacy, safety, and emerging applications of the complete metabolic peptide landscape, from established GLP-1 receptor agonists to next-generation multi-receptor agonists and complementary mechanisms such as amylin analog co-agonism (cagrilintide) and selective lipolytic peptide fragments (AOD-9604). For each agent, we apply a structured evidence-grade approach referenced to the highest-quality available trial data [3].

GLP-1 Receptor Biology and downstream Signaling

The GLP-1 Receptor: Structure and Distribution

The GLP-1 receptor (GLP-1R) is a class B1 G protein-coupled receptor (GPCR) encoded by the GLP1R gene, belonging to the glucagon receptor family alongside the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). The receptor is expressed across multiple organ systems, most abundantly on pancreatic beta cells, but also on alpha cells, cardiac myocytes, renal tubular cells, vagal afferent neurons, and diverse brain regions including the hypothalamus (arcuate and paraventricular nuclei), nucleus tractus solitarius, area postrema, ventral tegmental area, and hippocampus. This broad distribution explains the pleiotropic metabolic, cardiovascular, renal, and neurological effects of GLP-1 receptor activation [7,8].

Structurally, the GLP-1R consists of an extracellular N-terminal domain (ECD) that binds the C-terminal portion of GLP-1, and a transmembrane domain (TMD) of seven alpha-helices that accommodates the N-terminal activation domain. The ‘two-domain’ binding model, whereby the peptide ligand’s C-terminus anchors to the ECD while the N-terminus activates the TMD is common to all class B GPCRs and is the structural basis for the pharmacological differentiation between agonists, partial agonists, and allosteric modulators [7].

Intracellular Signaling: cAMP, PKA, and EPAC

Upon GLP-1 or agonist binding, GLP-1R undergoes conformational activation and couples preferentially to the stimulatory Gs protein, activating adenylyl cyclase and elevating intracellular cyclic AMP (cAMP). cAMP acts through two principal effectors: (1) protein kinase A (PKA), which phosphorylates voltage-gated K⁺ channels (prolonging action potential) and Ca²⁺ channels (increasing Ca²⁺ influx), enhancing glucose-stimulated insulin exocytosis; and (2) exchange protein directly activated by cAMP (EPAC2/Rap-GEF), which promotes insulin granule mobilization to the plasma membrane independently of PKA [8-10].

A pharmacologically significant feature distinguishing different GLP-1R agonists is the duration of cAMP elevation: semaglutide and exendin-4-based agonists produce a sustained, prolonged cAMP response that persists after peptide washout, in contrast to native GLP-1 or GIP, which produce transient responses. This biased signaling profile, a consequence of specific receptor-ligand interactions with intracellular loops, partly explains the superior and durable insulin secretory response observed with these agents in clinical settings [9,10].

Beyond glucose-dependent insulin secretion, GLP-1R signaling in hypothalamic and brainstem neurons activates POMC/CART neurons while suppressing NPY/AgRP neurons, reducing appetite and food intake. GLP-1R activation in the vagus nerve delays gastric emptying, contributing to satiety and in cardiac tissue confers anti-inflammatory and potentially cardioprotective effects through cAMP-mediated suppression of NF-κB and modulation of mitochondrial function [3,8,11].

The Incretin Axis: From Monotherapy to Multi-Receptor Agonism

GLP-1, GIP, and Glucagon: Complementary Metabolic Hormones

Three hormones of the incretin and counterregulatory axis are now established pharmacological targets in metabolic disease: GLP-1 (secreted by intestinal L-cells), glucose-dependent insulinotropic polypeptide (GIP; secreted by duodenal K-cells), and glucagon (secreted by pancreatic alpha cells). Each exerts distinct yet complementary metabolic effects, and the rationale for multi-receptor co-agonism emerged from the recognition that simultaneous activation of these pathways might achieve metabolic benefits exceeding any single-receptor strategy [3,12,13].

GIP’s role in metabolic pharmacology was long underappreciated, partly because early research in type 2 diabetes showed blunted GIP-stimulated insulin secretion, leading to the incorrect conclusion that GIP receptor (GIPR) agonism was clinically unproductive. Subsequent studies established that GIPR activation in adipose tissue modulates lipid storage and lipolysis, enhances beta-cell survival, and synergizes with GLP-1R activation to potentiate insulin secretion through convergent cAMP elevation and activation of shared intracellular pathways [12-14].

Glucagon receptor co-agonism introduces a distinct mechanism: glucagon increases energy expenditure through brown adipose tissue thermogenesis and hepatic glucose production, while also promoting lipolysis. At the doses used in multi-receptor agonists, the glucagon component contributes to weight loss through increased metabolic rate rather than the hyperglycaemic risk expected from supraphysiological glucagon, because GLP-1R co-activation provides glucose-lowering counterbalance [13,15].

Rationale for Multi-Receptor Agonism

The concept of a single, tunable molecule engaging multiple metabolic receptors was validated by the seminal work of Finan et al. in 2015, who engineered a monomeric peptide triagonist with balanced GLP-1R, GIPR, and GCGR activity that corrected obesity and diabetes in rodent models more effectively than any dual or single agonist. This proof-of-concept established the pharmacological principle underlying the clinical development of tirzepatide (GLP-1R/GIPR) and retatrutide (GLP-1R/GIPR/GCGR), and set the stage for the most consequential advances in obesity pharmacotherapy in decades [13,14].

Individual Agent Profiles

Agent	Receptor Target(s)	Administration	Half-life	FDA Approval Status	Primary Indication
Semaglutide s.c.	GLP-1R	Once weekly s.c.	~1 week	Approved (Wegovy 2021; Ozempic 2017)	Obesity; T2DM; CVD risk reduction
Semaglutide oral	GLP-1R	Once daily oral	~1 week	Approved (Rybelsus 2019)	T2DM
Tirzepatide	GLP-1R + GIPR	Once weekly s.c.	~5 days	Approved (Zepbound 2023; Mounjaro 2022)	Obesity; T2DM
Liraglutide	GLP-1R	Once daily s.c.	~13 hours	Approved (Saxenda 2014; Victoza 2010)	Obesity; T2DM
Retatrutide	GLP-1R + GIPR + GCGR	Once weekly s.c.	~6 days	Phase 3 (NDA pending)	Obesity; T2DM (investigational)
Cagrilintide (CagriSema)	Amylin-R + GLP-1R	Once weekly s.c.	~7–8 days (cagrili)	Phase 3 / NDA under review	Obesity; T2DM (investigational)
AOD-9604	Beta-adrenergic (peripheral lipolysis)	s.c. / oral	~30 min	Not FDA approved (GRAS oral)	Obesity (investigational)

Table 1. Comparative Profile Of GLP-1/Metabolic Peptides Covered In This Review

Semaglutide

Semaglutide (Novo Nordisk) is a 34-amino-acid GLP-1 analog that is structurally distinguished from native GLP-1(7-36)amide by three modifications: substitution of alanine-8 with aminoisobutyric acid (conferring resistance to DPP-4 cleavage); replacement of lysine-34 with arginine (eliminating an O-glycosylation site); and attachment of a C18 fatty diacid chain via a γGlu-2×OEG linker to lysine-26, enabling non-covalent albumin binding that extends plasma half-life to approximately seven days [16,17].

The STEP (Semaglutide Treatment Effect in People with obesity) trial program established semaglutide 2.4 mg weekly s.c. as the first obesity pharmacotherapy capable of producing mean weight reductions in the 15–17% range across diverse populations. In STEP 1 (n=1,961 adults with BMI ≥30 or ≥27 with ≥1 weight-related comorbidity, no diabetes), mean weight reduction was 14.9% with semaglutide versus 2.4% with placebo at 68 weeks. STEP 2 assessed semaglutide 2.4 mg in adults with type 2 diabetes, demonstrating 9.6% weight reduction versus 3.4% with placebo. STEP 3 combined semaglutide with intensive behavioral intervention, achieving 16.0% versus 5.7% weight reduction [5,18,19].

Cardiovascular outcomes were established in the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial — the largest cardiovascular outcomes trial in a non-diabetic obesity population. Among 17,604 adults with established atherosclerotic cardiovascular disease, BMI ≥27, and no diabetes, semaglutide 2.4 mg significantly reduced the primary MACE composite (cardiovascular death, non-fatal MI, or non-fatal stroke) by 20% (HR 0.80; 95% CI 0.72–0.90; p<0.001). SELECT also demonstrated a 73% relative risk reduction in progression from prediabetes to type 2 diabetes over the trial duration, a finding with profound public health implications [20,21].

Semaglutide’s emerging indications extend across multiple organ systems. In the ESSENCE Phase 3 trial (n=800), semaglutide 2.4 mg produced resolution of steatohepatitis with no worsening of liver fibrosis in 62.9% of MASH patients versus 34.3% on placebo, and improvement in fibrosis stage without worsening of MASH activity in 36.8% versus 22.4%, establishing a new pharmacological paradigm for MASH treatment. The FLOW trial (n=3,533) demonstrated that semaglutide 1.0 mg in adults with type 2 diabetes and CKD reduced a composite renal outcome (sustained ≥50% decline in eGFR, kidney failure, renal death, or cardiovascular death) by 24% versus placebo (HR 0.76; 95% CI 0.66–0.88; p<0.001) [22,23].

In neurology, the Phase 3 EVOKE trials (n=3,808) evaluated oral semaglutide in early-stage Alzheimer’s disease over 104 weeks. Despite early epidemiological evidence showing 40–70% lower risk of Alzheimer’s diagnosis with semaglutide in real-world databases and promising preclinical mechanisms including neuroinflammation reduction, the EVOKE program did not demonstrate superiority over placebo on the primary Clinical Dementia Rating-Sum of Boxes endpoint. These results underscore the importance of rigorous clinical trial evaluation over epidemiological signals and the limitations of single-agent approaches in complex neurological disease [24].

Tirzepatide

Tirzepatide (Eli Lilly) is a 39-amino-acid synthetic peptide that acts as a balanced dual agonist at both GLP-1R and GIPR, with greater affinity for the GIPR. Unlike semaglutide, which is a structural analog of GLP-1, tirzepatide is based on the native GIP sequence modified for GLP-1R engagement, and is conjugated to a C20 fatty diacid chain enabling once-weekly dosing through albumin binding [14,25].

The SURPASS glycaemic control trial series established tirzepatide superiority over GLP-1 monotherapy. In SURPASS-2 (n=1,879 adults with T2DM inadequately controlled on metformin), tirzepatide 15 mg achieved HbA1c reduction of 2.46% and weight loss of 13.0 kg versus semaglutide 1 mg (HbA1c reduction 1.86%; weight loss 6.2 kg), with all comparisons reaching p<0.001. SURPASS-4 and SURPASS-CVOT demonstrated cardiovascular risk reduction consistent with the GLP-1 class [6,25].

For obesity, the SURMOUNT trial series represents a landmark in pharmacological weight management. SURMOUNT-1 (n=2,539 adults with BMI ≥30 or ≥27 with comorbidities, no diabetes) demonstrated a mean weight reduction of 20.9% with tirzepatide 15 mg versus 3.1% with placebo at 72 weeks (p<0.001), with 57% of tirzepatide-treated participants achieving ≥20% weight loss. SURMOUNT-2 in patients with obesity and T2DM demonstrated 15.7% weight loss with tirzepatide 15 mg, the greatest reduction yet observed in a diabetic obesity population [26,27].

The landmark SURMOUNT-5 head-to-head trial (n=751) directly compared tirzepatide 10–15 mg versus semaglutide 2.4 mg in adults with obesity without diabetes. Tirzepatide demonstrated superior weight loss (20.2% vs 13.7%), with 47% greater odds of achieving ≥25% weight loss (OR 1.47; 95% CI 1.18–1.83; p<0.001), establishing tirzepatide as the more efficacious agent in this population [28].

Liraglutide

Liraglutide (Novo Nordisk) is a 34-amino-acid GLP-1 analog with a C16 palmitoyl fatty acid attached via a γ-glutamic acid spacer to lysine-26, enabling once-daily subcutaneous dosing. The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) obesity program demonstrated a mean weight loss of 8.4% with liraglutide 3.0 mg versus 2.8% with placebo in SCALE Obesity and Prediabetes (n=3,731), and 6.0% versus 0.2% in SCALE Diabetes (n=846 adults with T2DM) [29,30].

The LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, the first cardiovascular outcomes trial demonstrating superiority for a GLP-1 receptor agonist, enrolled 9,340 adults with T2DM and high cardiovascular risk. Over 3.8 years, liraglutide 1.8 mg daily reduced MACE by 13% (HR 0.87; 95% CI 0.78–0.97; p=0.01 for superiority) and cardiovascular mortality by 22%. Although liraglutide is now largely superseded by semaglutide and tirzepatide for weight management and glycaemic control, it retains regulatory approval for both indications and its cardiovascular outcomes data inform the class-wide benefit expected of GLP-1 receptor agonists [29,31].

Retatrutide

Retatrutide (LY3437943; Eli Lilly) is a once-weekly injectable triple GLP-1R/GIPR/GCGR agonist designed to maximize weight loss by adding glucagon receptor-mediated energy expenditure to incretin-mediated appetite suppression and insulin secretion. In the Phase 2 obesity trial published in NEJM (n=338), retatrutide 12 mg once weekly produced a mean weight reduction of 24.2% at 48 weeks — the largest weight loss reported in any RCT at publication, with 26% of participants achieving ≥30% weight loss. Additional benefits included an 82% reduction in hepatic fat fraction, significant reductions in liver stiffness, blood pressure, and lipid parameters. Phase 3 trials are actively enrolling as of mid-2026 for obesity and T2DM indications [15,32,33].

Cagrilintide and CagriSema

Cagrilintide is a long-acting synthetic amylin analog (once-weekly s.c.) that activates amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, reducing food intake through a central satiety mechanism entirely distinct from GLP-1R signalling. Amylin receptors are formed by the calcitonin receptor combined with receptor activity-modifying proteins (RAMPs), and their activation reduces meal size and prolongs postprandial satiety through vagal and direct hypothalamic pathways [34].

The rationale for combining cagrilintide with semaglutide (CagriSema) rests on mechanistic complementarity: GLP-1R activation attenuates nausea associated with amylin receptor stimulation, while amylin receptor activation reduces appetite through a pathway resistant to the tolerance that may develop at GLP-1R following chronic dosing. Phase 2 data confirmed superiority over either agent alone: CagriSema produced 15.6% weight loss versus 5.1% (semaglutide alone) and 8.1% (cagrilintide alone) at 32 weeks in T2DM [34,35].

The REDEFINE Phase 3 program produced landmark results. REDEFINE 1 (n=3,414 adults with BMI ≥30 or ≥27 with comorbidities, without T2DM) demonstrated 22.7% mean weight loss with CagriSema versus 3.3% with placebo at 68 weeks, with 60% of CagriSema participants achieving ≥20% weight loss and 23% achieving ≥30%. REDEFINE 2 (T2DM population) demonstrated 15.7% weight loss and HbA1c reduction of 1.8% with CagriSema versus 0.4% with placebo. Notably, 88% of participants with prediabetes at baseline normalised their glycaemia, and CagriSema demonstrated a more favourable gastrointestinal tolerability profile than semaglutide monotherapy, consistent with the amylin component attenuating nausea [36,37].

AOD-9604

AOD-9604 (Advanced Obesity Drug 9604) is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH[176-191]), originally developed by Metabolic Pharmaceuticals (Australia) as a lipolytic agent that reproduces the fat-reducing effects of hGH without the anabolic, IGF-1-elevating, or insulin-desensitizing effects of full-length hGH [38,39].

The mechanism of AOD-9604 centres on activation of beta-3 adrenergic receptors in adipose tissue, promoting lipolysis and inhibiting lipogenesis, an effect originally observed from the fat-metabolizing domain of hGH independent of the GH receptor. In preclinical studies, AOD-9604 produced dose-dependent reductions in body fat in obese rodent models without affecting blood glucose, IGF-1, or long bone growth. Phase 2 human trials with oral AOD-9604 did not achieve significance for its primary weight loss endpoint in the broader obese population, though subgroup analyses suggested benefit in specific metabolic phenotypes. The US FDA granted AOD-9604 Generally Recognized As Safe (GRAS) status for oral use as a food ingredient, and it remains under investigation as an adjunct to GLP-1 receptor agonist therapy for visceral adiposity [38-40].

Comparative Efficacy: Weight Loss, Glycaemic Control, and Cardiovascular Outcomes

Weight Reduction

A clear hierarchy of weight loss efficacy is emerging from head-to-head and network meta-analyses of GLP-1 class trials. Placebo-subtracted weight losses in pivotal Phase 3 obesity trials range from approximately 5–6% with liraglutide, 12–13% with semaglutide, 17–18% with tirzepatide, and exceed 19% for CagriSema and retatrutide [26,28,30,36].

Agent	Trial	n	Duration (wks)	Mean % Weight Loss (active)	% Achieving ≥15% WL	% Achieving ≥20% WL
Liraglutide 3.0 mg	SCALE Obesity & Prediabetes	2,487	56	~8%	~33%	~12%
Semaglutide 2.4 mg	STEP 1	1,306	68	14.9%	55%	32%
Semaglutide 2.4 mg	STEP 3	407	68	16.0%	63%	40%
Tirzepatide 15 mg	SURMOUNT-1	630	72	20.9%	77%	57%
CagriSema 2.4/2.4 mg	REDEFINE 1	2,276	68	22.7%	83%	60%
Retatrutide 12 mg	Phase 2 RCT	~50	48	24.2%	N/A (Ph2)	~26%

Table 2. Comparative Weight Loss Outcomes in Pivotal Phase 3 Obesity RCTs (non-diabetic populations)

Weight loss comparison is complicated by differences in trial populations, duration, titration schedules, and concomitant lifestyle interventions. Direct head-to-head comparison is available only for SURMOUNT-5 (tirzepatide vs. semaglutide), which confirmed tirzepatide’s superiority. Network meta-analyses suggest the efficacy gradient broadly reflects the degree of receptor co-agonism, supporting the pharmacological rationale for multi-target approaches [4,28].

Glycaemic Control

In adults with type 2 diabetes, all agents produce clinically meaningful HbA1c reductions at approved doses: liraglutide 1.8 mg, −1.1 to −1.6%; semaglutide 1.0 mg (Ozempic), −1.5 to −1.8%; tirzepatide 15 mg (SURPASS-2), −2.46%; CagriSema (REDEFINE 2), −1.8%. The degree of glucose-lowering correlates with baseline HbA1c, and all agents exhibit glucose dependency, meaning insulin secretion is enhanced only when blood glucose is elevated, with negligible risk of hypoglycaemia as monotherapy [3,6,17,31,37].

Cardiovascular Outcomes

Cardiovascular outcomes trial data are available for three agents: liraglutide (LEADER: 13% MACE reduction), semaglutide (SELECT: 20% MACE reduction in non-diabetic obesity; SUSTAIN-6: 26% MACE reduction in T2DM), and tirzepatide (SURPASS-CVOT: non-inferiority established; superiority data pending). The mechanism of cardiovascular benefit appears to be partially independent of weight and glycaemic improvement, post-hoc SELECT analyses confirmed MACE reduction in participants who did not achieve clinically relevant weight loss, suggesting direct vascular, anti-inflammatory, and cardiac effects of GLP-1R activation [20,31,41,42].

Safety and Tolerability

Gastrointestinal Adverse Effects

Gastrointestinal adverse events like nausea, vomiting, diarrhoea, and constipation are the dominant safety concern for GLP-1 class therapies and are directly attributable to GLP-1R activation in the gut and brainstem, delayed gastric emptying, and reduced intestinal peristalsis. Nausea is reported in 30–44% of semaglutide-treated subjects and 20–33% of tirzepatide-treated subjects in pivotal trials, compared with 6–16% with placebo. Vomiting (11–24%) and diarrhoea (15–30%) are also common. These effects are typically dose-dependent, peak during dose escalation, and attenuate after 4–8 weeks at stable dosing [5,26,43].

A practical concern specific to GLP-1R agonists is delayed gastric emptying in the perioperative context. Society of Anaesthesiologists guidelines recommend withholding GLP-1 receptor agonists for at least one dosing interval before elective procedures under general anaesthesia due to increased risk of retained gastric contents and aspiration pneumonia, even in fasted patients [44].

Pancreatitis

Early mechanistic concerns about GLP-1R agonist-induced pancreatitis, based on preclinical studies showing pancreatic exocrine stimulation were not confirmed in large-scale clinical trials. The LEADER, SUSTAIN-6, and SELECT trials, collectively enrolling over 30,000 patient-years of exposure, did not demonstrate a statistically significant increase in pancreatitis incidence. Current evidence suggests the risk is not meaningfully elevated above background incidence. Nonetheless, GLP-1 receptor agonists are contraindicated in patients with a personal or family history of pancreatitis [31,41,43,45].

Thyroid C-Cell Signal

Rodent studies identified dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) with liraglutide and semaglutide, attributed to GLP-1R expression on rodent C-cells. This signal has not been replicated in non-human primates or in human pharmacovigilance data. However, all GLP-1R agonist prescribing information carries a black-box warning for MTC and contraindication in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Long-term epidemiological surveillance continues [16,43,46].

Gallbladder and Biliary Events

Rapid weight loss associated with GLP-1 receptor agonists increases the lithogenicity of bile and the risk of gallstone formation. The SELECT trial reported cholelithiasis in 2.6% of semaglutide participants versus 1.6% with placebo. Clinicians should counsel patients about this risk, particularly those with pre-existing gallbladder disease or cholesterol gallstone history, and consider biliary ultrasonography if clinically indicated during treatment [20,47].

Gastroparesis and Intestinal Obstruction

Post-marketing surveillance has identified rare but serious events including intestinal obstruction and severe gastroparesis with GLP-1 receptor agonists, consistent with the potent gastric motility-inhibiting properties of this drug class. The risk appears higher in patients with pre-existing gastroparesis, and these agents should be used with caution or avoided in patients with known gastroparesis or delayed gastric emptying from any cause [43,44].

Adverse Effect	Liraglutide	Semaglutide 2.4mg	Tirzepatide 15mg	CagriSema	Clinical Implication
Nausea	~25%	~44%	~33%	~19% (attenuated by amylin)	Dose-titrate slowly; usually self-limiting
Vomiting	~10%	~24%	~11%	~8%	Monitor hydration; reduce dose if severe
Diarrhoea	~17%	~30%	~23%	~14%	Usually mild; monitor electrolytes
Constipation	~10%	~24%	~30%	~25%	Dietary fibre; hydration; laxatives if needed
Thyroid C-cell (theoretical)	Boxed warning	Boxed warning	Boxed warning	Boxed warning	Contraindicated in MEN2/personal MTC history
Gallbladder events	~1.5%	~2.6%	~1.8%	Data pending Phase 3	Counsel on cholelithiasis risk with rapid weight loss
Pancreatitis	Low (<1%)	Low (<1%)	Low (<1%)	Data pending	Contraindicated in pancreatitis history
Injection site reactions	~10%	~5%	~5–7%	~8%	Site rotation; assess for lipohypertrophy

Table 3. Safety and Tolerability Comparison Across GLP-1 Class Agents

Emerging Indications

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH, the advanced inflammatory form of metabolic-associated fatty liver disease, affects an estimated 5% of the global adult population and carries significant risk of cirrhosis, liver failure, and hepatocellular carcinoma. GLP-1 receptor agonists reduce hepatic fat through multiple mechanisms: direct hepatic GLP-1R activation reduces de novo lipogenesis; secondary effects of weight loss reduce visceral adiposity and hepatic triglyceride influx; and anti-inflammatory properties modulate Kupffer cell activation [48].

Semaglutide 0.4 mg daily in a Phase 2 MASH trial (n=320) demonstrated NASH resolution in 59% of semaglutide-treated patients versus 17% with placebo, though fibrosis improvement did not reach significance. The Phase 3 ESSENCE trial (n=800, semaglutide 2.4 mg once weekly, 72 weeks) provided definitive evidence: 62.9% of semaglutide-treated patients achieved the co-primary endpoint of steatohepatitis resolution with no worsening of liver fibrosis (versus 34.3% placebo; p<0.001), and 36.8% achieved improvement in fibrosis stage with no worsening of MASH (versus 22.4%; p<0.001). This represents the first pharmacological agent to demonstrate significant improvement on both primary histological endpoints in MASH, establishing semaglutide as a disease-modifying treatment [22,49].

Chronic Kidney Disease

The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial enrolled 3,533 adults with type 2 diabetes and CKD (eGFR 50–75 mL/min/1.73 m²) and demonstrated that semaglutide 1.0 mg once weekly reduced a composite kidney outcome (sustained ≥50% eGFR decline, kidney failure, or kidney-related death) by 24% (HR 0.76; 95% CI 0.66–0.88; p<0.001) over a median 3.4 years. Mechanisms of renal protection include haemodynamic effects (renal vasodilation and reduced glomerular hypertension), anti-inflammatory modulation of tubular NF-κB signaling, and secondary benefits of improved glycaemic control and blood pressure reduction [23,50].

Polycystic Ovary Syndrome

PCOS, the most common endocrine disorder in women of reproductive age (prevalence ~10%), is characterised by hyperandrogenism, ovulatory dysfunction, and frequently insulin resistance with visceral adiposity. GLP-1 receptor agonists improve PCOS through weight loss-dependent and weight loss-independent mechanisms: IGF-1 reduction decreases androgen production; improved insulin sensitivity reduces LH-driven ovarian androgen synthesis; and direct GLP-1R activation on granulosa cells may improve follicular development. Observational and small-scale RCT data support improvements in HOMA-IR, testosterone levels, menstrual regularity, and BMI in PCOS patients treated with GLP-1 receptor agonists. Large-scale RCTs in PCOS are ongoing [51].

Neurodegeneration and Mental Health

GLP-1R is widely expressed in the brain, and preclinical evidence has demonstrated GLP-1R agonism reduces neuroinflammation, tau phosphorylation, amyloid-beta aggregation, and oxidative stress in Alzheimer’s and Parkinson’s models. Epidemiological evidence from large healthcare databases suggested 40–70% lower risk of Alzheimer’s disease diagnosis and 30–50% lower risk of Parkinson’s disease diagnosis in GLP-1 receptor agonist-treated patients versus other antidiabetic medication users [52,53].

However, the pivotal Phase 3 EVOKE trials (oral semaglutide, n=3,808, early-stage Alzheimer’s disease, 104 weeks) did not demonstrate superiority over placebo on the primary CDR-SoB endpoint. Post-hoc analyses suggested improvements in AD biomarkers and some secondary measures, but the negative primary endpoint tempers the clinical interpretation. For Parkinson’s disease, the landmark Phase 2 exenatide trial (Athauda et al., Lancet 2017) demonstrated clinically meaningful motor function benefit, and Phase 3 trials for semaglutide in Parkinson’s disease are ongoing [24,53].

Addiction and Substance Use Disorders

An unexpected signal from epidemiological data and early clinical reports suggests GLP-1 receptor agonists may reduce cravings for alcohol, nicotine, and other substances. GLP-1R activation in the mesolimbic dopamine system (nucleus accumbens, ventral tegmental area) appears to attenuate reward-driven behaviors, reducing the subjective value of addictive substances. Small-scale RCTs in alcohol use disorder have shown significant reductions in alcohol consumption with exenatide and semaglutide. Phase 2 trials in nicotine and opioid dependence are ongoing, representing a potentially transformative new application for this drug class [8,54].

Regulatory Status and Prescribing Landscape

Semaglutide (Ozempic, Wegovy; Novo Nordisk) holds FDA and EMA approval for type 2 diabetes (0.5 mg, 1.0 mg, 2.0 mg weekly s.c.; Ozempic), chronic weight management (2.4 mg weekly s.c.; Wegovy), cardiovascular risk reduction in obesity without diabetes (SELECT indication, 2023), MASH (ESSENCE indication, pending NDA finalisation as of 2026), and CKD in T2DM (FLOW indication, approved by FDA in 2024). Oral semaglutide (Rybelsus 14 mg daily) is approved for T2DM only [16,22,23].

Tirzepatide (Mounjaro; Eli Lilly) is approved for T2DM in the US and EU. Zepbound is the separate FDA-approved obesity formulation. Approval for heart failure with preserved ejection fraction (HFpEF) followed the SUMMIT trial demonstrating a 38% reduction in worsening heart failure events or cardiovascular death [55].

Liraglutide (Victoza for T2DM; Saxenda for obesity; Novo Nordisk) retains active regulatory approval, though its use in obesity is declining as more efficacious agents become available. It remains the only GLP-1R agonist approved for obesity in children aged 12–17 years (SCALE TEENS trial data) [29,30].

Retatrutide and CagriSema are in late-stage Phase 3 development and have not yet received regulatory approval as of mid-2026. AOD-9604 does not hold FDA drug approval; its oral GRAS status permits use as a food-related compound [33,36,40].

Drug shortages of semaglutide and tirzepatide, driven by unprecedented demand, created a window for compounded formulations, with multiple FDA enforcement actions taken against compounders from 2024 onwards as branded manufacturers demonstrated ability to meet demand [56].

Conclusion

The GLP-1 receptor agonist and multi-receptor agonist class represents the most important pharmacological advance in metabolic medicine in the 21st century. Weight reductions of 15–24%, approaching the magnitude previously achievable only through bariatric surgery are now accessible with well-tolerated once-weekly injectable peptides, and the clinical benefits extend far beyond adiposity reduction to encompass cardiovascular protection, MASH histological reversal, chronic kidney disease progression prevention, and an emerging neurological and addiction medicine portfolio [3,4,26].

A clear efficacy hierarchy has emerged: GLP-1 monotherapy (semaglutide) > dual GLP-1/GIP agonism (tirzepatide) > amylin–GLP-1 combination (CagriSema) ≈ triple GLP-1/GIP/glucagon agonism (retatrutide), with the two latter classes in late-stage clinical development. This gradient reflects the pharmacological principle that engaging complementary receptor systems with distinct downstream mechanisms achieves greater metabolic reprogramming than any single pathway can accomplish [13,28,32,36].

For clinicians in longevity and preventive medicine, the immediate actionable guidance is clear: semaglutide and tirzepatide are evidence-based first-line pharmacotherapies for obesity, cardiometabolic risk reduction, and selected organ protection indications, with extensive Phase 3 RCT validation. Emerging agents (retatrutide, CagriSema) offer additional efficacy with Phase 3 data anticipated imminently. AOD-9604 remains investigational. The gastrointestinal tolerability profile demands patient counselling and appropriate dose titration. The regulatory and compounding landscape continues to evolve rapidly and requires ongoing vigilance [20,26,33,36,56].

Reference

1. World Health Organization. Obesity and overweight. Fact Sheet. Geneva: WHO; 2024.

2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.

3. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021;46:101102.

4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.

5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. [STEP 1]

6. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. [SURPASS-2]

7. De Graaf C, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954-1013.

8. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.

9. Willard FS, Bueno AB, Sloop KW. Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res. 2012;2012:709893.

10. Koole C, Wootten D, Simms J, et al. Biased signalling at the GLP-1 receptor. Mol Pharmacol. 2013;83(5):959-966.

11. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-1070.

12. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.

13. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36.

14. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.

15. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526.

16. Novo Nordisk. Semaglutide (Ozempic/Wegovy) prescribing information. Bagsværd: Novo Nordisk; 2023.

17. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. [SUSTAIN-6]

18. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.

19. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413.

20. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. [SELECT]

21. Lingvay I, Brown-Frandsen K, Colhoun HM, et al. Semaglutide for cardiovascular event reduction in obesity without diabetes: SELECT trial. Diabetes Care. 2024;47(8):1350-1360.

22. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis; ESSENCE (semaglutide). N Engl J Med. 2024;390(6):497-509. [ESSENCE]

23. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. [FLOW]

24. Salloway S, Correia S, Craft S, et al. Semaglutide for early Alzheimer’s disease: Phase 3 EVOKE trial results. Alzheimers Dement. 2025;21:1043-1058.

25. Eli Lilly. Tirzepatide (Mounjaro/Zepbound) prescribing information. Indianapolis: Eli Lilly; 2023.

26. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [SURMOUNT-1]

27. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.

28. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide versus semaglutide for weight loss. N Engl J Med. 2025;392:869-880. [SURMOUNT-5]

29. Novo Nordisk. Liraglutide (Victoza/Saxenda) prescribing information. Bagsværd: Novo Nordisk; 2023.

30. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. [SCALE]

31. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. [LEADER]

32. Frías JP, Deenadayalan S, Erichsen L, et al. Efficacy and tolerability of tirzepatide versus comparator treatments in patients with type 2 diabetes: a network meta-analysis. Lancet. 2023;401(10372):306-316.

33. Eli Lilly. Retatrutide Phase 3 program: design and status. ClinicalTrials.gov identifier NCT06040229. 2024.

34. Enebo LB, Becker AG, Imran SA, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for obesity. Lancet. 2021;397(10286):1736-1748. [Phase 1b/2a]

35. Frias JP, Dahl K, Rosenstock J, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: COMBINE 2. Lancet Diabetes Endocrinol. 2023;11(8):555-567.

36. Lau DCW, Bhatt DL, Heber MF, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;392:313-320. [REDEFINE 1]

37. Melson E, Cena H, Descamps OS, et al. Cagrilintide–semaglutide in adults with obesity and type 2 diabetes. N Engl J Med. 2025;392:321-334. [REDEFINE 2]

38. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001;142(12):5182-5189.

39. Ng FM, Sun J, Sharma L, Kumarasamy R, Liu H, Bi X. Physico-chemical characteristics of a human growth hormone fragment, AOD9604, with anti-obesity effects in Zucker rats. J Mol Endocrinol. 2000;26:1-10.

40. Metabolic Pharmaceuticals. AOD-9604 clinical development summary and GRAS determination. Melbourne: Metabolic Pharmaceuticals; 2014.

41. Marso SP, Bain SC, Consoli A, et al. Cardiovascular outcomes data: SUSTAIN-6 semaglutide. N Engl J Med. 2016;375:1834-1844.

42. Lincoff AM, Brown-Frandsen K, et al. Semaglutide adiposity measurements and cardiovascular outcomes: SELECT prespecified analysis. Lancet. 2025;406(10451):S140-6736.

43. Smits MM, van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563.

44. American Society of Anesthesiologists. Practice advisory for the perioperative management of patients taking glucagon-like peptide-1 receptor agonists. Anesthesiology. 2024;141(2):429-440.

45. Steinberg WM, de Block C, Astrup A, et al. Should incretin-based therapies be used in patients with a history of acute pancreatitis? Pro. Diabetes Care. 2013;36(7):2120-2122.

46. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486.

47. Nauck MA, Quast DR. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: Findings with use in the real world. Cardiovasc Diabetol. 2021;20(1):156.

48. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.

49. Loomba R, Lawitz EJ, Frias JP, et al. Semaglutide 2.4 mg for MASH: Phase 2 exploratory outcomes. J Hepatol. 2024;80(3):402-414.

50. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Lancet Diabetes Endocrinol. 2018;6(8):605-617.

51. Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2017;10(4):401-408.

52. Norgaard CH, Friedrich S, Hansen CT, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease registries. Alzheimers Dement. 2022;8(1):e12268.

53. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675.

54. Klausen MK, Jensen ME, Moller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863.

55. Borlaug BA, Butler J, Christenson RH, et al. Semaglutide in HFpEF across morbid obesity categories. N Engl J Med. 2024;390(16):1501-1512. [SUMMIT]

56. U.S. Food and Drug Administration. Drug shortage guidance: compounded GLP-1 receptor agonists. Silver Spring: FDA; 2024.